POLK and cancer: Future studies should examine whether the loss of Polk in human cancers can be exploited in human cancer therapy and predict responsiveness to platinating agents, and whether cisplatin sensitivity of Polk-deficient cells is caused by sensitivity to cisplatin-induced intrastrand or interstrand crosslinks.